Table 1.
Number of incident and prevalent melanoma cases by sex, and melanoma cause-specific and all-cause mortality of melanoma patients (melanoma cause-specific mortality for 2019 is not available in the CSO database yet).
| Incident population | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients with new Melanoma diagnosis (n, % of population at risk) | 2,426 | 0.02% | 2,360 | 0.02% | 2,503 | 0.03% | 2,557 | 0.03% | 2,803 | 0.03% | 2,684 | 0.03% | 2,673 | 0.03% | 2,528 | 0.03% | 2,414 | 0.02% |
| Male (n, % of new M patients) | 1,201 | 49.51% | 1,077 | 45.64% | 1,201 | 47.98% | 1,221 | 47.75% | 1,346 | 48.02% | 1,279 | 47.65% | 1,314 | 49.16% | 1,182 | 46.76% | 1,169 | 48.43% |
| Female (n, % of new M patients) | 1,225 | 50.49% | 1,283 | 54.36% | 1,302 | 52.02% | 1,336 | 52.25% | 1,457 | 51.98% | 1,405 | 52.35% | 1,359 | 50.84% | 1,346 | 53.24% | 1,245 | 51.57% |
| Prevalent population | ||||||||||||||||||
| Patients with Melanoma diagnosis (n, % of total population) | 15,388 | 0.15% | 17,041 | 0.17% | 18,773 | 0.19% | 20,546 | 0.21% | 22,481 | 0.23% | 24,228 | 0.25% | 25,939 | 0.27% | 27,365 | 0.28% | 28,660 | 0.29% |
| Male (n, % of new M patients) | 6,582 | 42.77% | 7,235 | 42.46% | 7,994 | 42.58% | 8,779 | 42.73% | 9,662 | 42.98% | 10,387 | 42.87% | 11,156 | 43.01% | 11,728 | 42.86% | 12,277 | 42.84% |
| Female (n, % of new M patients) | 8,806 | 57.23% | 9,806 | 57.54% | 10,779 | 57.42% | 11,767 | 57.27% | 12,819 | 57.02% | 13,841 | 57.13% | 14,783 | 56.99% | 15,637 | 57.14% | 16,383 | 57.16% |
| Cause specific mortality | ||||||||||||||||||
| Patients died based on CSO (n, % of prevalent population) | 363 | 2.36% | 377 | 2.21% | 347 | 1.85% | 378 | 1.84% | 349 | 1.55% | 337 | 1.39% | 333 | 1.28% | 317 | 1.16% | ||
| Male (n, % of new M patients) | 213 | 58.68% | 210 | 55.70% | 184 | 53.03% | 193 | 51.06% | 215 | 61.60% | 198 | 58.75% | 188 | 56.46% | 177 | 55.84% | ||
| Female (n, % of new M patients) | 150 | 41.32% | 167 | 44.30% | 163 | 46.97% | 185 | 48.94% | 134 | 38.40% | 139 | 41.25% | 145 | 43.54% | 140 | 44.16% | ||
| All-cause mortality | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |||||||||
| Patients died based on NHIF (n, % of prevalent population) | 707 | 4.59% | 771 | 4.52% | 784 | 4.18% | 868 | 4.22% | 937 | 4.17% | 962 | 3.97% | 1,102 | 4.25% | 1,119 | 4.09% | 1,183 | 4.13% |
| Male (n, % of new M patients) | 424 | 59.97% | 442 | 57.33% | 436 | 55.61% | 463 | 53.34% | 554 | 59.12% | 545 | 56.65% | 610 | 55.35% | 620 | 55.41% | 665 | 56.21% |
| Female (n, % of new M patients) | 283 | 40.03% | 329 | 42.67% | 348 | 44.39% | 405 | 46.66% | 383 | 40.88% | 417 | 43.35% | 492 | 44.65% | 499 | 44.59% | 518 | 43.79% |
CSO, Central Statistical Office; M, melanoma; NHIF, National Health Insurance Fund.